Anthrax sub-unit vaccine: The structural consequences of binding rPA83 to Alhydrogel®
- 31 January 2012
- journal article
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 80 (1) , 25-32
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cellsJournal of Experimental Medicine, 2008
- Aluminum hydroxide adjuvant produced under constant reactant concentrationJournal of Pharmaceutical Sciences, 2006
- Immunogenicity of Recombinant Protective Antigen and Efficacy against Aerosol Challenge with AnthraxInfection and Immunity, 2005
- Aluminium compounds for use in vaccinesImmunology & Cell Biology, 2004
- Alanine-scanning Mutations in Domain 4 of Anthrax Toxin Protective Antigen Reveal Residues Important for Binding to the Cellular Receptor and to a Neutralizing Monoclonal AntibodyJournal of Biological Chemistry, 2003
- Measuring the surface area of aluminum hydroxide adjuvantJournal of Pharmaceutical Sciences, 2002
- Involvement of Domain 3 in Oligomerization by the Protective Antigen Moiety of Anthrax ToxinJournal of Bacteriology, 2001
- Anthrax Protective Antigen: Prepore-to-Pore ConversionBiochemistry, 1999
- Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY 146032 and phospholipid membranesBiochemistry, 1988
- Vaccine AdjuvantsClinical Infectious Diseases, 1980